Myriad Genetics (NASDAQ:MYGN) has been given a $41.00 target price by stock analysts at BTIG Research in a research report issued on Tuesday. The firm presently has a “buy” rating on the stock. BTIG Research’s price objective would suggest a potential upside of 11.29% from the stock’s previous close.
MYGN has been the topic of several other research reports. Morgan Stanley restated an “underweight” rating and issued a $24.00 price target (up previously from $17.00) on shares of Myriad Genetics in a report on Friday, October 6th. Barclays restated a “hold” rating and issued a $30.00 price target on shares of Myriad Genetics in a report on Monday, January 8th. Zacks Investment Research upgraded shares of Myriad Genetics from a “hold” rating to a “strong-buy” rating and set a $42.00 price target on the stock in a report on Tuesday, October 17th. ValuEngine upgraded shares of Myriad Genetics from a “hold” rating to a “buy” rating in a report on Friday, November 10th. Finally, Stephens set a $45.00 price target on shares of Myriad Genetics and gave the company a “buy” rating in a report on Wednesday, January 3rd. Two equities research analysts have rated the stock with a sell rating, nine have issued a hold rating and three have given a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average price target of $30.09.
Myriad Genetics (NASDAQ MYGN) opened at $36.84 on Tuesday. Myriad Genetics has a 1-year low of $15.15 and a 1-year high of $37.30. The company has a debt-to-equity ratio of 0.09, a current ratio of 2.34 and a quick ratio of 2.06. The company has a market cap of $2,550.00, a P/E ratio of 24.89, a P/E/G ratio of 2.29 and a beta of 0.24.
In other news, VP Richard M. Marsh sold 13,759 shares of Myriad Genetics stock in a transaction that occurred on Friday, January 12th. The shares were sold at an average price of $36.25, for a total transaction of $498,763.75. Following the sale, the vice president now owns 136,385 shares in the company, valued at $4,943,956.25. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Walter Phd Gilbert sold 7,500 shares of Myriad Genetics stock in a transaction that occurred on Thursday, December 14th. The shares were sold at an average price of $33.19, for a total transaction of $248,925.00. The disclosure for this sale can be found here. Insiders have sold 30,290 shares of company stock worth $1,044,590 in the last quarter. Insiders own 6.70% of the company’s stock.
Institutional investors and hedge funds have recently bought and sold shares of the company. Meeder Asset Management Inc. raised its stake in shares of Myriad Genetics by 1,067.4% during the third quarter. Meeder Asset Management Inc. now owns 3,292 shares of the company’s stock valued at $119,000 after purchasing an additional 3,010 shares during the period. SG Americas Securities LLC purchased a new stake in shares of Myriad Genetics during the second quarter valued at approximately $101,000. Riverhead Capital Management LLC raised its stake in shares of Myriad Genetics by 80.9% during the second quarter. Riverhead Capital Management LLC now owns 4,161 shares of the company’s stock valued at $107,000 after purchasing an additional 1,861 shares during the period. Commonwealth Equity Services Inc purchased a new stake in shares of Myriad Genetics during the third quarter valued at approximately $202,000. Finally, Teacher Retirement System of Texas purchased a new stake in shares of Myriad Genetics during the third quarter valued at approximately $204,000.
ILLEGAL ACTIVITY NOTICE: “Myriad Genetics (MYGN) PT Set at $41.00 by BTIG Research” was originally posted by StockNewsTimes and is the sole property of of StockNewsTimes. If you are viewing this piece of content on another website, it was stolen and republished in violation of U.S. and international trademark and copyright law. The original version of this piece of content can be viewed at https://stocknewstimes.com/2018/01/18/myriad-genetics-mygn-pt-set-at-41-00-by-btig-research.html.
About Myriad Genetics
Myriad Genetics, Inc is a molecular diagnostic company. The Company is engaged in the discovery, development and marketing of transformative molecular diagnostic tests. The Company operates through two segments: diagnostics and other. The diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual’s risk for developing disease later in life, identify a patient’s likelihood of responding to drug therapy and guide a patient’s dosing to enable optimal treatment, or assess a patient’s risk of disease progression and disease recurrence.
Receive News & Ratings for Myriad Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics and related companies with MarketBeat.com's FREE daily email newsletter.